IL5 and hypereosinophilic syndrome: Monoclonal antibodies targeting IL-5 or its receptor are not approved for treatment of HES but have been available for selected patients through clinical trial participation and/or compassionate use (34) (NCT002446686 for mepolizumab, an anti-IL-5 antibody).